The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working with regulators to ensure stable ongoing supply for the one-time gene therapy ...
The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more ...
CSL Behring has identified what it will take to win in a major autoimmune market. Ahead of a potential approval of argenx’s rival drug, the company surveyed people with chronic inflammatory ...
The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results